There is increasing evidence that deficient clearance of β-amyloid (Aβ) contributes to its
accumulation in late-onset Alzheimer disease (AD). Several Aβ-degrading enzymes, including …

Background Hyperactivity of the classical axis of the renin-angiotensin system (RAS),
mediated by angiotensin II (Ang II) activation of the angiotensin II type 1 receptor (AT1R), is …

In a collaboration involving 11 groups with research interests in cerebral amyloid angiopathy
(CAA), we used a two-stage process to develop and in turn validate a new consensus …

Neprilysin (NEP) degrades amyloid-β (Aβ) and is thought to contribute to its clearance from
the brain. In Alzheimer disease (AD), downregulation of NEP has been suggested to …

Experimental reduction of neprilysin (NEP) or insulin-degrading enzyme (IDE) in vivo
exacerbates β-amyloid accumulation in the brain. The level of these enzymes is reportedly …

There is wide recognition of a complex association between midlife hypertension and
cardiovascular disease and later development of Alzheimer’s disease (AD) and cognitive …

Lecanemab, an anti-amyloid antibody with effects on biomarker and clinical endpoints in
early Alzheimer's Disease (AD), was granted accelerated approval by the FDA in 2023 and …

Background: Centrally acting angiotensin converting enzyme inhibitors (CACE-Is) are
associated with reduced rates of cognitive decline in patients with dementia. CACE-Is may also …

Background Drugs modifying angiotensin II signalling could reduce Alzheimer's disease
pathology, thus decreasing the rate of disease progression. We investigated whether the …

Background Hyperlipidemia and hypertension are modifiable risk factors for Alzheimer’s
disease and related dementias (ADRD). Approximately 25% of adults over age 65 use both …